Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.01
Quick Ratio7.98
Price-To-Earnings
Trailing P/E Ratio-5.23
Forward P/E Ratio-4.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.48 million
Price / Sales120.37
Cash FlowN/A
Price / CashN/A
Book Value$0.69 per share
Price / Book4.70
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-77,990,000.00
Net MarginsN/A
Return on Equity-103.81%
Return on Assets-86.88%
Miscellaneous
Employees103
Outstanding Shares166,440,000
Market Cap$539.28 million
Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions
What is Rigel Pharmaceuticals' stock symbol?
Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."
How were Rigel Pharmaceuticals' earnings last quarter?
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.16). The biotechnology company earned $1.79 million during the quarter, compared to analysts' expectations of $0.30 million. View Rigel Pharmaceuticals' Earnings History.
When is Rigel Pharmaceuticals' next earnings date?
What price target have analysts set for RIGL?
7 brokerages have issued 1-year price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Rigel Pharmaceuticals' share price to reach $8.2143 in the next twelve months. This suggests a possible upside of 153.5% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.
What is the consensus analysts' recommendation for Rigel Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.
What are Wall Street analysts saying about Rigel Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (8/14/2018)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and $7.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from Tavalisse without any current contribution from pipeline assets. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (8/9/2018)
- 3. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating on Rigel Pharmaceuticals and our 12-month price target of $9 per share, following Rigel’s 2Q18 financial results call. Rigel hosted a conference call and provided an update on its initial commercial launch of TAVALISSE (fostamatinib) in immune thrombocytopenia (ITP), which began at the end of May 2018. On the call, Rigel announced additional details on the commercial launch, including positive feedback from prescribing physicians and anecdotal evidence of TAVALISSE’s benefit for patients. We are encouraged by the strong positive uptake within just a month of commercial availability of the product and have adjusted our model for the quarter." (8/8/2018)
Are investors shorting Rigel Pharmaceuticals?
Rigel Pharmaceuticals saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 16,038,929 shares, a decline of 10.2% from the August 15th total of 17,868,240 shares. Based on an average daily trading volume, of 3,001,477 shares, the days-to-cover ratio is presently 5.3 days. Approximately 9.9% of the shares of the company are sold short. View Rigel Pharmaceuticals' Current Options Chain.
Who are some of Rigel Pharmaceuticals' key competitors?
Some companies that are related to Rigel Pharmaceuticals include TESARO (TSRO), Global Blood Therapeutics (GBT), Pacira Pharmaceuticals (PCRX), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Mirati Therapeutics (MRTX), G1 Therapeutics (GTHX), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA), Puma Biotechnology (PBYI), Enanta Pharmaceuticals (ENTA), Zogenix (ZGNX), Phibro Animal Health (PAHC) and Clovis Oncology (CLVS).
Who are Rigel Pharmaceuticals' key executives?
Rigel Pharmaceuticals' management team includes the folowing people:
- Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 57)
- Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53)
- Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 59)
- Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 57)
- Dr. Thomas A. Raffin, Co-Founder (Age 71)
Who are Rigel Pharmaceuticals' major shareholders?
Rigel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.74%), BlackRock Inc. (8.19%), Millennium Management LLC (1.98%), Boxer Capital LLC (1.40%), Northern Trust Corp (1.20%) and Macquarie Group Ltd. (0.96%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Eldon C Mayer III, Raul R Rodriguez and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.
Which major investors are selling Rigel Pharmaceuticals stock?
RIGL stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Millennium Management LLC, Baker BROS. Advisors LP, DAFNA Capital Management LLC, California Public Employees Retirement System and NJ State Employees Deferred Compensation Plan. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Ryan D Maynard. View Insider Buying and Selling for Rigel Pharmaceuticals.
Which major investors are buying Rigel Pharmaceuticals stock?
RIGL stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Stonepine Capital Management LLC, Sio Capital Management LLC, Macquarie Group Ltd., B. Riley Financial Inc., Bank of America Corp DE and Northern Trust Corp. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.
How do I buy shares of Rigel Pharmaceuticals?
Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rigel Pharmaceuticals' stock price today?
One share of RIGL stock can currently be purchased for approximately $3.24.
How big of a company is Rigel Pharmaceuticals?
Rigel Pharmaceuticals has a market capitalization of $539.28 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.
What is Rigel Pharmaceuticals' official website?
How can I contact Rigel Pharmaceuticals?
Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]
MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
